Literature DB >> 22437349

Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer.

Constantina Petraki1, Youssef M Youssef, William Dubinski, Zsuzsanna Lichner, Andreas Scorilas, Maria D Pasic, Vassilios Komborozos, Bishoy Khalil, Catherine Streutker, Eleftherios P Diamandis, George M Yousef.   

Abstract

The prognosis of patients with colorectal cancer (CRC) is assessed through conventional clinicopathological parameters, which are not always accurate. Members of the human kallikrein-related peptidases gene family represent potential cancer biomarkers. The aim of this study was to investigate the expression of human tissue kallikrein-related peptidase 10 (KLK10) by immunohistochemistry in CRC, to correlate this expression with various histopathological and clinical variables, and to evaluate its significance as a predictor of disease outcome. KLK10 expression was evaluated by immunohistochemistry and a combined expression score was calculated for each case based on intensity and percentage of positivity. A statistically significant positive association was observed between KLK10 and tumor stage and liver metastases (p = 0.015 and p = 0.035, respectively). Paradoxically, a negative association was observed between KLK10 and tumor grade (p = 0.009). Kaplan-Meier survival curves and univariate analysis showed that both KLK10 expression and stage had statistically significant correlations with disease-free survival (DFS) (p = 0.030 and p < 0.001, respectively) and overall survival (p = 0.010 and p = 0.001, respectively). Cox multivariate analysis showed that both KLK10 expression and stage were independent predictors of unfavorable DFS (p = 0.057 and p = 0.001, respectively) and overall survival (p = 0.009 and p = 0.001, respectively). In conclusion, KLK10 immunostaining is an independent prognostic marker in patients with CRC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22437349     DOI: 10.1007/s13277-012-0368-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

Review 1.  The human kallikrein gene family: new biomarkers for ovarian cancer.

Authors:  George M Yousef; Eleftherios P Diamandis
Journal:  Cancer Treat Res       Date:  2009

Review 2.  Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?

Authors:  Olivia L Tan; Astrid K Whitbread; Judith A Clements; Ying Dong
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

Review 3.  Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.

Authors:  Konstantinos Mavridis; Andreas Scorilas
Journal:  Future Oncol       Date:  2010-02       Impact factor: 3.404

4.  [Expression and single nucleotide polymorphisms of kallikrein 10 in colorectal cancer].

Authors:  Bo Feng; Min-hua Zheng; Jun-jun Ma; Qu Cai; Yi Zhang; Jun Ji; Ying Qu; Jian-wen Li; Ai-guo Lu; Ming-liang Wang; Bing-ya Liu; Zheng-gang Zhu
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2006-05-01

5.  Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression.

Authors:  X L Liu; D E Wazer; K Watanabe; V Band
Journal:  Cancer Res       Date:  1996-07-15       Impact factor: 12.701

6.  Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.

Authors:  Nicole M White; Anna Bui; Salvador Mejia-Guerrero; Julie Chao; Antoninus Soosaipillai; Youssef Youssef; Marina Mankaruos; R John Honey; Robert Stewart; Kenneth T Pace; Linda Sugar; Eleftherios P Diamandis; Jules Doré; George M Yousef
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

7.  Parallel overexpression of seven kallikrein genes in ovarian cancer.

Authors:  George M Yousef; Mary-Ellen Polymeris; George M Yacoub; Andreas Scorilas; Antoninus Soosaipillai; Cynthia Popalis; Stefano Fracchioli; Dionyssios Katsaros; Eleftherios P Diamandis
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

Review 8.  Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2008-08-07       Impact factor: 8.327

9.  Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer.

Authors:  M Kioulafa; L Kaklamanis; E Stathopoulos; D Mavroudis; V Georgoulias; E S Lianidou
Journal:  Ann Oncol       Date:  2009-01-15       Impact factor: 32.976

10.  The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer.

Authors:  M Talieri; L Li; Y Zheng; D K Alexopoulou; A Soosaipillai; A Scorilas; D Xynopoulos; E P Diamandis
Journal:  Br J Cancer       Date:  2009-04-14       Impact factor: 7.640

View more
  7 in total

1.  MiR-194-3p modulates the progression of colorectal cancer by targeting KLK10.

Authors:  Tao Liu; Yuejun Fang
Journal:  Histol Histopathol       Date:  2021-12-22       Impact factor: 2.303

2.  Prospective quantitative gene expression analysis of kallikrein-related peptidase KLK10 as a diagnostic biomarker for childhood acute lymphoblastic leukemia.

Authors:  Shwan Majid Ahmad; Basima Sadq Ahmed; Karzan Ghafur Khidhir; Heshu Sulaiman Rahman
Journal:  PeerJ       Date:  2022-05-31       Impact factor: 3.061

3.  Association between IL-4 -589C>T polymorphism and colorectal cancer risk.

Authors:  Qiang Li; Qian Wang; Xiaoyan Xu; Songtao Ren; Li Wang
Journal:  Tumour Biol       Date:  2013-11-12

4.  Association between IRS-1 Gly972Arg polymorphism and colorectal cancer risk.

Authors:  Peng Li; Lingjun Wang; Lihua Liu; Hong Jiang; Chong Ma; Tao Hao
Journal:  Tumour Biol       Date:  2014-04-03

5.  Biomarker implication of kallikrein-related peptidases as prognostic tissue substrates of poor survival in colorectal cancer.

Authors:  Qiliang Peng; Yi Shen; Peifeng Zhao; Ming Cheng; Yongyou Wu; Yaqun Zhu
Journal:  Cancer Cell Int       Date:  2020-06-22       Impact factor: 5.722

6.  KLK8 promotes the proliferation and metastasis of colorectal cancer via the activation of EMT associated with PAR1.

Authors:  Qing Hua; Zhirong Sun; Yi Liu; Xuefang Shen; Weiwei Zhao; Xiaoyan Zhu; Pingbo Xu
Journal:  Cell Death Dis       Date:  2021-09-22       Impact factor: 8.469

7.  Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application.

Authors:  Zhiqiao Zhang; Tingshan He; Liwen Huang; Yanling Ouyang; Jing Li; Yiyan Huang; Peng Wang; Jianqiang Ding
Journal:  J Transl Med       Date:  2019-12-03       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.